Matches in SemOpenAlex for { <https://semopenalex.org/work/W4244238644> ?p ?o ?g. }
Showing items 1 to 49 of
49
with 100 items per page.
- W4244238644 endingPage "10" @default.
- W4244238644 startingPage "3" @default.
- W4244238644 abstract "After completing this course, the reader will be able to: Describe the latest literature on the use of topotecan in recurrent ovarian cancer. Compare and contrast the efficacy and safety of topotecan with other agents used for the treatment of recurrent ovarian cancer. Identify the toxicity profile of topotecan in recurrent ovarian cancer patients. Access and take the CME test online and receive one hour of AMA PRA category 1 credit at CME.TheOncologist.com Ovarian cancer is the fifth leading cause of cancer death in women. Most patients with ovarian cancer respond to first-line chemotherapy, but many relapse within 18 to 22 months. The development of efficacious salvage therapies that increase overall survival while maintaining quality of life is a great challenge in the treatment of this disease. Topotecan, a novel topoisomerase I inhibitor, is currently indicated for the treatment of recurrent metastatic carcinoma of the ovary. In patients with relapsed ovarian cancer, the overall response rates on treatment with topotecan range from 19%-33% in platinum-sensitive patients, 14%-18% in platinum-resistant patients, and 5%-11% in platinum-refractory patients. The proportion of patients achieving stable disease ranges between 17% in refractory and 48% in sensitive patients. In phase III studies, topotecan was shown to be equivalent in efficacy to both paclitaxel and liposomal doxorubicin as second-line therapy in patients with relapsed ovarian cancer. Further, non-cross-resistance between topotecan and paclitaxel was demonstrated in a third-line, phase III crossover study, suggesting that topotecan may be effective in the first-line setting with paclitaxel and/or platinum. Hematologic toxicities include neutropenia, thrombocytopenia, and anemia; however, these toxicities are usually short lived, noncumulative, and manageable with dose modifications, including low-dose topotecan regimens. Nonhematologic toxicities are usually mild to moderate in severity. These data support the use of topotecan for second-line therapy and suggest that topotecan may also be effective in first-line therapy. Further studies with topotecan alone and in combination with other agents are needed to fully characterize the role and sequencing of topotecan in the salvage and first-line settings." @default.
- W4244238644 created "2022-05-12" @default.
- W4244238644 creator A5008763534 @default.
- W4244238644 date "2002-10-01" @default.
- W4244238644 modified "2023-10-14" @default.
- W4244238644 title "Update on the Role of Topotecan in the Treatment of Recurrent Ovarian Cancer" @default.
- W4244238644 doi "https://doi.org/10.1634/theoncologist.7-2004-3" @default.
- W4244238644 hasPublicationYear "2002" @default.
- W4244238644 type Work @default.
- W4244238644 citedByCount "0" @default.
- W4244238644 crossrefType "journal-article" @default.
- W4244238644 hasAuthorship W4244238644A5008763534 @default.
- W4244238644 hasBestOaLocation W42442386441 @default.
- W4244238644 hasConcept C121608353 @default.
- W4244238644 hasConcept C126322002 @default.
- W4244238644 hasConcept C143998085 @default.
- W4244238644 hasConcept C2776694085 @default.
- W4244238644 hasConcept C2777292972 @default.
- W4244238644 hasConcept C2780427987 @default.
- W4244238644 hasConcept C2781209748 @default.
- W4244238644 hasConcept C71924100 @default.
- W4244238644 hasConceptScore W4244238644C121608353 @default.
- W4244238644 hasConceptScore W4244238644C126322002 @default.
- W4244238644 hasConceptScore W4244238644C143998085 @default.
- W4244238644 hasConceptScore W4244238644C2776694085 @default.
- W4244238644 hasConceptScore W4244238644C2777292972 @default.
- W4244238644 hasConceptScore W4244238644C2780427987 @default.
- W4244238644 hasConceptScore W4244238644C2781209748 @default.
- W4244238644 hasConceptScore W4244238644C71924100 @default.
- W4244238644 hasIssue "90005" @default.
- W4244238644 hasLocation W42442386441 @default.
- W4244238644 hasOpenAccess W4244238644 @default.
- W4244238644 hasPrimaryLocation W42442386441 @default.
- W4244238644 hasRelatedWork W187925780 @default.
- W4244238644 hasRelatedWork W1989495864 @default.
- W4244238644 hasRelatedWork W2059474539 @default.
- W4244238644 hasRelatedWork W2072767112 @default.
- W4244238644 hasRelatedWork W2105623825 @default.
- W4244238644 hasRelatedWork W2410995755 @default.
- W4244238644 hasRelatedWork W2461409983 @default.
- W4244238644 hasRelatedWork W2466209479 @default.
- W4244238644 hasRelatedWork W2736441140 @default.
- W4244238644 hasRelatedWork W2968124559 @default.
- W4244238644 hasVolume "7" @default.
- W4244238644 isParatext "false" @default.
- W4244238644 isRetracted "false" @default.
- W4244238644 workType "article" @default.